Bullish Case: Known: VOR is mean-reverting; inferred from the VOR return surface, the highest relative likelihood concentrates near modest returns across holding windows. Calibration: my April 45% rebound-to-$19–$20 view matches today’s $20.05. Uncertain: telitacicept interpretation and dilution risk. If SPY IV doesn’t spike further and updates stay non-negative, a grind toward low-$20s is the higher-supported bullish path.

Bearish Case: Known: VOR mean-reversion doesn’t remove tail risk; the VOR return surface still shows thinner negative downside bands. Inferred: SPY’s IV surface has elevated near-term front-end and downside skew, so risk-off can transmit quickly. Uncertain: adverse telitacicept Phase 3/safety read or an ATM/secondary. Aug 10 USTR drug-pricing comments and H1’27 catalysts could amplify volatility (direction uncertain).

Potential Outcomes:

1. 45%: $19–$21 drift; invalid if 2 closes <$18.8.
2. 25%: $18–$19.5 range; invalid if >$21.5 or <$17.8.
3. 20%: ≤$17.5 on dilution/ATM; trigger = announced secondary/ATM.
4. 10%: $14–$16 shock; trigger = adverse telitacicept update or SPY front-end IV spike.

July 22, 2026